Media Advisory - AnorMED Inc. Teleconference call notification

Apr 04, 2001, 01:00 ET from AnorMED Inc.

    VANCOUVER, April 4 /PRNewswire/ - On Thursday, April 5th, 2001 AnorMED
 Inc. will hold a teleconference call at 8:00 a.m. EST (5:00 a.m PST) to
 discuss an update on the development of ZD0473. To participate in the
 teleconference please dial, 1-888-209-3777 before 8:00 a.m. EST. This call
 will be taped, available one hour after the teleconference, and on replay
 until April 10th. To hear a complete replay please call 1-416-626-4100. The
 reservation number required for access is No. 18505956. This call will also be
 audiocast from AnorMED's website at www.anormed.com.
 
     AnorMED is a biopharmaceutical company focused on the discovery and
 development of small molecule therapeutic products for the treatment of a
 variety of diseases, including cancer and HIV. The Company has multiple
 products in clinical development. Foznol, which AnorMED has exclusively
 licensed to Shire Pharmaceuticals plc, has been filed for market approval in
 Europe for the treatment of excess phosphate levels associated with kidney
 failure. Phase III trials for Foznol are ongoing in the US. In addition, the
 Company has two products in Phase II and one in Phase I, as well as a diverse
 pipeline of product candidates in early stage development. AnorMED's business
 strategy includes aggressively advancing the most promising of its therapeutic
 products to a point where the most favorable terms for corporate partnerships
 and licenses can be negotiated. AnorMED has three such agreements in place
 with AstraZeneca plc of London, U.K., DuPont Pharmaceutical Company of
 Wilmington, Delaware, and Shire Pharmaceuticals Group plc of Basingstoke, U.K.
 
 

SOURCE AnorMED Inc.
    VANCOUVER, April 4 /PRNewswire/ - On Thursday, April 5th, 2001 AnorMED
 Inc. will hold a teleconference call at 8:00 a.m. EST (5:00 a.m PST) to
 discuss an update on the development of ZD0473. To participate in the
 teleconference please dial, 1-888-209-3777 before 8:00 a.m. EST. This call
 will be taped, available one hour after the teleconference, and on replay
 until April 10th. To hear a complete replay please call 1-416-626-4100. The
 reservation number required for access is No. 18505956. This call will also be
 audiocast from AnorMED's website at www.anormed.com.
 
     AnorMED is a biopharmaceutical company focused on the discovery and
 development of small molecule therapeutic products for the treatment of a
 variety of diseases, including cancer and HIV. The Company has multiple
 products in clinical development. Foznol, which AnorMED has exclusively
 licensed to Shire Pharmaceuticals plc, has been filed for market approval in
 Europe for the treatment of excess phosphate levels associated with kidney
 failure. Phase III trials for Foznol are ongoing in the US. In addition, the
 Company has two products in Phase II and one in Phase I, as well as a diverse
 pipeline of product candidates in early stage development. AnorMED's business
 strategy includes aggressively advancing the most promising of its therapeutic
 products to a point where the most favorable terms for corporate partnerships
 and licenses can be negotiated. AnorMED has three such agreements in place
 with AstraZeneca plc of London, U.K., DuPont Pharmaceutical Company of
 Wilmington, Delaware, and Shire Pharmaceuticals Group plc of Basingstoke, U.K.
 
 SOURCE AnorMED Inc.